cbdMD Inc (YCBD) Q1 2026 Earnings Call Highlights: Strategic Acquisitions and Financial …

GuruFocus News

Wed, February 18, 2026 at 2:01 PM GMT+9 3 min read

In this article:

YCBD

+10.72%

This article first appeared on GuruFocus.

Release Date: February 17, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

cbdMD Inc (YCBD) regained compliance with NYC listing requirements, improving its market standing.

The company completed a $2.25 million Series C preferred financing, enhancing liquidity and working capital.

A $20 million equity line of credit was structured, providing financial flexibility under favorable market conditions.

Net loss per share improved significantly from $1.73 to $0.04, reflecting better financial management.

The acquisition of Bluebird Botanicals is expected to unlock synergies and expand the customer base.

Negative Points

Net sales slightly decreased from $5.1 million to $5 million compared to the prior year period.

Gross margin declined from 66% to 60%, primarily due to increased warehouse expenses and a shift to more wholesale revenue.

Loss from operations increased to $286,000 from $86,000 in the prior year period.

The regulatory environment remains uncertain, with potential industry-wide impacts from restrictive hemp legislation.

The Herbal Oasis line of seltzers is still a small contributor to overall sales, indicating slower-than-expected growth in this segment.

Q & A Highlights

Warning! GuruFocus has detected 4 Warning Signs with YCBD.

Is YCBD fairly valued? Test your thesis with our free DCF calculator.

Q: Can you provide more insight into the integration of Bluebird Botanicals and any potential opportunities for SKU rationalization? A: We have brought over several team members from Bluebird Botanicals. The acquisition provides access to a new customer base and allows us to optimize our supply chain and SKU base. We see opportunities for growth by improving marketing activities and aligning some of our SKUs with Bluebird’s customer needs. - Unidentified_1

Q: Will you integrate Bluebird’s e-commerce capabilities with cbdMD’s, or maintain them as separate brands? A: We plan to maintain them as separate brands. The customer bases are slightly different, and we believe there is an opportunity to grow each brand independently. - Unidentified_1

Q: Can you provide any insight into the Herbal Oasis line of seltzers and its contribution to sales? A: We haven’t published specific data, but the Herbal Oasis line is starting to contribute to sales. It remains small relative to the core cbdMD brand, but we expect improvement throughout the year and will reassess what we disclose as gains are realized. - Unidentified_1

Story Continues  

Q: What are the financial highlights for the first quarter of fiscal 2026? A: Net sales were $5 million, a 12% sequential increase. Gross margin was 60%, down from 66% the prior year due to increased warehouse expenses and a shift to more wholesale revenue. The net loss was $325,000, a substantial improvement from the prior year’s $1 million loss. - Unidentified_2

Q: What are the strategic priorities moving forward? A: Our priorities include driving revenue improvement, integrating Bluebird Botanicals, maintaining cost discipline, and navigating the regulatory landscape. We believe our strong cash position supports a meaningful long-term runway. - Unidentified_1

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Terms and Privacy Policy

Privacy Dashboard

More Info